Literature DB >> 28255804

Conversion from immediate- to extended-release cysteamine may decrease disease control and increase additional side effects.

Sören Bäumner1, Lutz T Weber2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28255804     DOI: 10.1007/s00467-017-3618-3

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


× No keyword cloud information.
  1 in total

1.  Switching from immediate- to extended-release cysteamine in nephropathic cystinosis patients: a retrospective real-life single-center study.

Authors:  Thurid Ahlenstiel-Grunow; Nele K Kanzelmeyer; Kerstin Froede; Martin Kreuzer; Jens Drube; Christian Lerch; Lars Pape
Journal:  Pediatr Nephrol       Date:  2016-06-27       Impact factor: 3.714

  1 in total
  1 in total

1.  Nephropathic Cystinosis: Symptoms, Treatment, and Perspectives of a Systemic Disease.

Authors:  Sören Bäumner; Lutz T Weber
Journal:  Front Pediatr       Date:  2018-03-14       Impact factor: 3.418

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.